Engineering Targeting Materials for Therapeutic Cancer Vaccines.
cancer
immunoengineering
immunotherapy
material engineering
targeting strategies
vaccines
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
10
2019
accepted:
10
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
Therapeutic cancer vaccines constitute a valuable tool to educate the immune system to fight tumors and prevent cancer relapse. Nevertheless, the number of cancer vaccines in the clinic remains very limited to date, highlighting the need for further technology development. Recently, cancer vaccines have been improved by the use of materials, which can strongly enhance their intrinsic properties and biodistribution profile. Moreover, vaccine efficacy and safety can be substantially modulated through selection of the site at which they are delivered, which fosters the engineering of materials capable of targeting cancer vaccines to specific relevant sites, such as within the tumor or within lymphoid organs, to further optimize their immunotherapeutic effects. In this review, we aim to give the reader an overview of principles and current strategies to engineer therapeutic cancer vaccines, with a particular focus on the use of site-specific targeting materials. We will first recall the goal of therapeutic cancer vaccination and the type of immune responses sought upon vaccination, before detailing key components of cancer vaccines. We will then present how materials can be engineered to enhance the vaccine's pharmacokinetic and pharmacodynamic properties. Finally, we will discuss the rationale for site-specific targeting of cancer vaccines and provide examples of current targeting technologies.
Identifiants
pubmed: 32117911
doi: 10.3389/fbioe.2020.00019
pmc: PMC7026271
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
19Subventions
Organisme : NCI NIH HHS
ID : R01 CA219304
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA253248
Pays : United States
Informations de copyright
Copyright © 2020 Briquez, Hauert, de Titta, Gray, Alpar, Swartz and Hubbell.
Références
Front Pharmacol. 2018 Mar 05;9:185
pubmed: 29556198
Biomaterials. 2011 Jul;32(20):4574-83
pubmed: 21474175
Genome Med. 2016 Jun 20;8(1):69
pubmed: 27323951
Ann Oncol. 2018 Nov 1;29(11):2163-2174
pubmed: 30295695
Angew Chem Int Ed Engl. 2015 May 26;54(22):6567-70
pubmed: 25873209
ACS Nano. 2012 May 22;6(5):4157-68
pubmed: 22486623
Sci Transl Med. 2017 Nov 8;9(415):
pubmed: 29118259
J Exp Clin Cancer Res. 2012 May 16;31:47
pubmed: 22592077
ACS Nano. 2014 May 27;8(5):4385-94
pubmed: 24766522
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Small. 2015 Apr;11(13):1519-25
pubmed: 25641795
Nanomedicine (Lond). 2018 Jul;13(13):1535-1549
pubmed: 30028251
Front Immunol. 2019 May 22;10:1078
pubmed: 31231358
Int J Mol Sci. 2018 Dec 04;19(12):
pubmed: 30518103
Cancer Metastasis Rev. 2011 Mar;30(1):83-95
pubmed: 21249423
Cancer Res. 2016 Mar 15;76(6):1517-27
pubmed: 26759238
Front Immunol. 2018 Nov 28;9:2796
pubmed: 30546366
Adv Drug Deliv Rev. 2019 Feb 15;141:67-91
pubmed: 30201522
Cancer Immunol Res. 2015 Jan;3(1):26-36
pubmed: 25127875
Adv Drug Deliv Rev. 2001 Aug 23;50(1-2):3-20
pubmed: 11489331
Nat Rev Immunol. 2014 Mar;14(3):195-208
pubmed: 24566916
Sci Immunol. 2017 Nov 10;2(17):
pubmed: 29127106
Methods Mol Biol. 2010;626:287-309
pubmed: 20099135
Artif Cells Nanomed Biotechnol. 2018;46(sup2):295-305
pubmed: 30043651
Oncol Res Treat. 2018;41(4):166-171
pubmed: 29562226
Biomedicines. 2018 Sep 25;6(4):
pubmed: 30257488
Front Immunol. 2018 Apr 26;9:866
pubmed: 29755464
Crit Rev Oncol Hematol. 2013 Sep;87(3):239-55
pubmed: 23415641
Mol Ther. 2011 Aug;19(8):1538-46
pubmed: 21629222
Cancer Res. 2004 Jul 15;64(14):4973-9
pubmed: 15256471
Immunol Cell Biol. 2005 Oct;83(5):451-61
pubmed: 16174093
Molecules. 2019 Sep 27;24(19):
pubmed: 31569697
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19902-7
pubmed: 24248387
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Int J Nanomedicine. 2012;7:5577-91
pubmed: 23144561
Int J Pharm. 2018 Sep 5;548(1):707-720
pubmed: 30012508
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Cancer Immunol Res. 2017 May;5(5):347-354
pubmed: 28465452
Ann Oncol. 2012 Jul;23(7):1788-95
pubmed: 22056974
Nat Rev Drug Discov. 2005 Jun;4(6):477-88
pubmed: 15931257
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11613-8
pubmed: 18697944
Hum Vaccin Immunother. 2014;10(11):3261-9
pubmed: 25625929
Nat Rev Immunol. 2012 Jul 13;12(8):557-69
pubmed: 22790179
Front Immunol. 2018 Jan 04;8:1751
pubmed: 29379493
Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6656-61
pubmed: 21464325
Nat Rev Immunol. 2018 Jan;18(1):5-18
pubmed: 28920587
Oncoimmunology. 2017 Nov 20;7(3):e1393598
pubmed: 29399390
Eur J Med Chem. 2017 Oct 20;139:542-563
pubmed: 28837920
Chin J Cancer. 2014 Feb;33(2):80-6
pubmed: 23845143
Molecules. 2017 Aug 23;22(9):
pubmed: 28832535
J Transl Med. 2005 Feb 21;3(1):9
pubmed: 15723705
JCI Insight. 2016 May 19;1(7):e87102
pubmed: 27699265
J Immunother. 2007 Feb-Mar;30(2):227-33
pubmed: 17471169
J Biomater Sci Polym Ed. 2016;27(1):40-54
pubmed: 26489768
Chem Sci. 2013 Jun;4(6):2319-2333
pubmed: 24077675
Wien Med Wochenschr. 2016 May;166(7-8):196-204
pubmed: 26861668
J Am Chem Soc. 2012 Mar 7;134(9):3965-7
pubmed: 22339432
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Eur J Pharm Biopharm. 2017 Apr;113:229-239
pubmed: 28034806
Cell Death Dis. 2017 Jun 1;8(6):e2836
pubmed: 28569770
Eur J Pharm Biopharm. 2000 Jul;50(1):27-46
pubmed: 10840191
Nat Rev Cancer. 2006 Jun;6(6):449-58
pubmed: 16723991
Nanotechnol Sci Appl. 2012 Sep 07;5:87-100
pubmed: 24198499
Methods. 2006 Sep;40(1):1-9
pubmed: 16997708
Biomaterials. 2014 Feb;35(5):1735-43
pubmed: 24290696
Trends Pharmacol Sci. 2018 Aug;39(8):766-781
pubmed: 30032745
Trends Immunol. 2019 Feb;40(2):142-158
pubmed: 30639050
Pharmaceuticals (Basel). 2018 Apr 09;11(2):
pubmed: 29642542
Cancer Lett. 2019 Apr 28;448:31-39
pubmed: 30731107
Blood. 2002 May 1;99(9):3319-25
pubmed: 11964299
Cancer Res. 2002 Aug 1;62(15):4282-8
pubmed: 12154030
Curr Opin Immunol. 2015 Apr;33:55-63
pubmed: 25665467
Cancer Cell. 2004 May;5(5):443-53
pubmed: 15144952
Front Immunol. 2014 Apr 08;5:149
pubmed: 24782858
Trends Biotechnol. 2014 Sep;32(9):448-55
pubmed: 25086728
Blood. 2011 Dec 22;118(26):6726-7
pubmed: 22194392
Tumour Biol. 2017 May;39(5):1010428317701628
pubmed: 28468593
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):148-156
pubmed: 26928656
Cancers (Basel). 2015 Dec 11;7(4):2443-58
pubmed: 26690480
Immunohorizons. 2018 Jul 2;2(6):185-197
pubmed: 31022686
J Clin Invest. 1997 Dec 1;100(11):2757-65
pubmed: 9389740
Biomaterials. 2012 Dec;33(36):9246-58
pubmed: 23031530
Cancer Immunol Immunother. 2017 Sep;66(9):1229-1241
pubmed: 28501941
Oncoimmunology. 2018 Jan 5;7(3):e1408749
pubmed: 29399414
Bioconjug Chem. 2010 Nov 17;21(11):1939-42
pubmed: 20936793
Nat Med. 1998 May;4(5):594-600
pubmed: 9585234
Nat Rev Immunol. 2009 Jan;9(1):28-38
pubmed: 19079136
Ind Eng Chem Res. 2017 May 24;56(20):5761-5777
pubmed: 28572701
J Cell Sci. 2002 Feb 15;115(Pt 4):849-56
pubmed: 11865040
Oncotarget. 2015 Jul 20;6(20):18081-93
pubmed: 26098776
Adv Healthc Mater. 2015 Jun 3;4(8):1203-14
pubmed: 25800699
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Theranostics. 2016 Aug 07;6(11):1887-98
pubmed: 27570558
Nature. 1998 Jun 4;393(6684):474-8
pubmed: 9624003
Nat Immunol. 2010 Dec;11(12):1127-35
pubmed: 20972432
Nat Rev Cancer. 2004 Jul;4(7):528-39
pubmed: 15229478
Biochim Biophys Acta. 1997 Sep 4;1328(2):261-72
pubmed: 9315622
Clin Cancer Res. 2008 Apr 1;14(7):1931-7
pubmed: 18381930
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
Nanomedicine (Lond). 2016 Mar;11(6):673-92
pubmed: 27003448
Biomed Res Int. 2015;2015:948501
pubmed: 26161423
Biomaterials. 2014 Jan;35(1):269-277
pubmed: 24099710
Cancer Immunol Res. 2016 Oct;4(10):858-868
pubmed: 27549123
Vaccine. 2002 Dec 19;20 Suppl 4:A28-31
pubmed: 12477425
Sci Rep. 2015 Feb 24;5:8569
pubmed: 25708982
Pharmacol Ther. 2015 Feb;146:120-31
pubmed: 25281915
Nat Rev Clin Oncol. 2016 Jun;13(6):370-83
pubmed: 27000958
Nat Immunol. 2015 Sep;16(9):927-32
pubmed: 26193080
Biomed J. 2018 Apr;41(2):118-128
pubmed: 29866600
J Genet Syndr Gene Ther. 2013 Aug 9;4:
pubmed: 24294541
Cancer Immunol Immunother. 2019 Oct;68(10):1681-1688
pubmed: 30944963
Nat Nanotechnol. 2012 Apr 08;7(6):383-8
pubmed: 22484912
Cancer Gene Ther. 2016 Jun;23(6):162-7
pubmed: 27056671
Vaccine. 2000 Jan 6;18(11-12):1051-8
pubmed: 10590325
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Cancer Immunol Res. 2014 May;2(5):436-47
pubmed: 24795356
Theranostics. 2016 Mar 21;6(6):762-72
pubmed: 27162548
J Cancer. 2017 Jun 1;8(8):1466-1476
pubmed: 28638462
Front Immunol. 2018 Mar 02;9:384
pubmed: 29559971
Nat Mater. 2013 Nov;12(11):978-90
pubmed: 24150416
Nanoscale. 2014 Nov 7;6(21):12273-86
pubmed: 25251024
Sci Transl Med. 2017 Sep 13;9(407):
pubmed: 28904226
Hum Vaccin Immunother. 2015;11(6):1368-86
pubmed: 25874884
Vaccines (Basel). 2015 May 08;3(2):390-407
pubmed: 26343193
Int J Pharm. 2006 Jan 3;307(1):93-102
pubmed: 16303268
J Exp Med. 2004 Mar 15;199(6):815-24
pubmed: 15024047
Cancer Chemother Pharmacol. 2016 Oct;78(4):815-24
pubmed: 27566701
Gynecol Oncol. 2014 Nov;135(2):371-81
pubmed: 25158037
J Control Release. 2018 Mar 28;274:1-8
pubmed: 29382546
J Natl Cancer Inst. 2017 Apr 1;109(4):
pubmed: 28376158
Front Immunol. 2019 Feb 08;10:187
pubmed: 30800130
Nanomedicine. 2016 Jan;12(1):131-41
pubmed: 26518604
Cancer Cell. 2015 Oct 12;28(4):500-514
pubmed: 26461094
Sci Rep. 2019 Mar 8;9(1):3945
pubmed: 30850643
Mol Biol Res Commun. 2016 Dec;5(4):201-214
pubmed: 28261624
Cancer Microenviron. 2010 Mar 19;3(1):83-95
pubmed: 21209776
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Ann Transl Med. 2017 May;5(10):221
pubmed: 28603736
Nature. 2008 Apr 3;452(7187):580-9
pubmed: 18385732
Nature. 2015 Mar 19;519(7543):366-9
pubmed: 25762141
Trends Cancer. 2018 Feb;4(2):119-137
pubmed: 29458962
Cold Spring Harb Perspect Biol. 2018 Oct 1;10(10):
pubmed: 29254979
Biomaterials. 2011 Apr;32(12):3322-9
pubmed: 21315444
Cancer Lett. 2001 Oct 10;171(2):153-64
pubmed: 11520599
Nat Commun. 2018 Jan 9;9(1):130
pubmed: 29317633
Cell Stem Cell. 2019 Jan 3;24(1):25-40
pubmed: 30595497
ACS Nano. 2015 Feb 24;9(2):1150-60
pubmed: 25597243
Oncotarget. 2018 Jun 22;9(48):29007-29017
pubmed: 29989043
Mol Cell Biol. 2013 Feb;33(4):800-14
pubmed: 23230268
Mol Ther Nucleic Acids. 2018 Mar 2;10:9-27
pubmed: 29499959
Immunol Cell Biol. 2019 Aug;97(7):664-674
pubmed: 31009109
Clin Cancer Res. 2014 Apr 1;20(7):1747-56
pubmed: 24691639
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Nanomedicine (Lond). 2014 Jan;9(1):121-34
pubmed: 24354814
Science. 2014 Feb 21;343(6173):885-8
pubmed: 24558160
Biomaterials. 2007 Dec;28(35):5344-57
pubmed: 17825905
Clin Transl Med. 2017 Dec 11;6(1):44
pubmed: 29230567
Transfus Med Hemother. 2019 Feb;46(1):36-46
pubmed: 31244580
Theranostics. 2017 Apr 10;7(6):1650-1662
pubmed: 28529642
Sci Rep. 2016 Feb 17;6:18205
pubmed: 26883295
Mol Cancer Ther. 2018 Jan;17(1):183-195
pubmed: 28939555
Ann Oncol. 2019 Jun 1;30(6):884-896
pubmed: 30912805
Cancer Treat Rev. 2003 Aug;29(4):297-307
pubmed: 12927570
J Control Release. 2010 Nov 1;147(3):408-12
pubmed: 20691741
Bioorg Med Chem Lett. 2007 Feb 1;17(3):617-20
pubmed: 17113288
Oncoimmunology. 2016 Jul 8;5(9):e1207842
pubmed: 27757300
Hum Vaccin Immunother. 2017 May 4;13(5):1112-1114
pubmed: 28118089
Genes (Basel). 2016 May 26;7(6):
pubmed: 27240403
Adv Mater. 2012 Jul 17;24(27):3659-65
pubmed: 22678851
Neoplasia. 2018 Aug;20(8):848-856
pubmed: 30025228
Int J Mol Sci. 2017 Jun 30;18(7):
pubmed: 28665313
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
ACS Nano. 2016 Oct 25;10(10):9274-9286
pubmed: 27680575
Clin Cancer Res. 2013 Jan 1;19(1):148-57
pubmed: 23172881
Am J Cancer Res. 2017 Oct 01;7(10):2091-2102
pubmed: 29119057
Drugs. 2012 Dec 3;72(17):2207-22
pubmed: 23116250
Cancer Res. 2015 Dec 1;75(23):5008-13
pubmed: 26573795
Nat Rev Immunol. 2016 Feb;16(2):102-11
pubmed: 26781939
Trends Biotechnol. 2014 Sep;32(9):456-65
pubmed: 24998519
Antioxid Redox Signal. 2014 Aug 10;21(5):786-803
pubmed: 24219144
Biomaterials. 2019 Oct;219:119373
pubmed: 31374479
FEBS J. 2011 Jan;278(1):16-27
pubmed: 21087457
Onco Targets Ther. 2018 Oct 04;11:6505-6524
pubmed: 30323625
Cancer Res. 2008 Sep 15;68(18):7530-40
pubmed: 18794141
J Immunother. 2008 Oct;31(8):714-22
pubmed: 18779748
J Control Release. 2006 May 1;112(1):26-34
pubmed: 16529839
Sci Transl Med. 2019 Apr 10;11(487):
pubmed: 30971453
Mol Ther. 2013 Jan;21(1):109-18
pubmed: 22968478
Biomacromolecules. 2012 Mar 12;13(3):652-63
pubmed: 22263698
Theranostics. 2017 Aug 17;7(14):3504-3516
pubmed: 28912891
Expert Opin Drug Deliv. 2014 Sep;11(9):1449-70
pubmed: 24870351
Nat Mater. 2019 Feb;18(2):175-185
pubmed: 30643235
Pharmacol Ther. 2016 Sep;165:32-49
pubmed: 27235391
Bioconjug Chem. 2010 Apr 21;21(4):653-62
pubmed: 20369815
Cancer Res. 2007 Jan 15;67(2):593-9
pubmed: 17234768
Eur J Immunol. 2013 Oct;43(10):2543-53
pubmed: 23784881
Acta Biomater. 2017 Sep 15;60:232-243
pubmed: 28479490
J Control Release. 2016 Dec 28;244(Pt A):108-121
pubmed: 27871992
Int J Cancer. 2006 Mar 15;118(6):1331-9
pubmed: 16381025
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Oncogene. 2016 Nov 17;35(46):5931-5941
pubmed: 27086930
Stem Cell Res Ther. 2016 Jan 11;7:7
pubmed: 26753925
J Immunother. 2011 Apr;34(3):251-63
pubmed: 21389873
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
J Am Chem Soc. 2003 Apr 16;125(15):4451-9
pubmed: 12683815
Colloids Surf B Biointerfaces. 2012 Nov 1;99:116-26
pubmed: 22078927
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9353-E9361
pubmed: 30213851
J Cell Sci. 2010 Dec 15;123(Pt 24):4195-200
pubmed: 21123617
Biomacromolecules. 2016 Aug 8;17(8):2507-13
pubmed: 27303825
Sci Transl Med. 2019 Jun 26;11(498):
pubmed: 31243150
Trends Mol Med. 2012 Sep;18(9):564-74
pubmed: 22917663
Sci Transl Med. 2016 Sep 21;8(357):357ra123
pubmed: 27655849
Mol Ther Methods Clin Dev. 2019 Jan 26;12:248-265
pubmed: 30815511
Nanoscale Res Lett. 2019 Jul 9;14(1):228
pubmed: 31289961
J Am Chem Soc. 2019 Mar 20;141(11):4510-4514
pubmed: 30768257
J Pharmacol Exp Ther. 2019 Aug;370(2):231-241
pubmed: 31175219
Hematol Oncol Clin North Am. 2019 Apr;33(2):199-214
pubmed: 30832995
J Immunother Cancer. 2018 Dec 12;6(1):146
pubmed: 30541631
Cancer Res. 2013 May 15;73(10):2943-8
pubmed: 23440426
Adv Exp Med Biol. 2010;667:111-23
pubmed: 20665204
Theranostics. 2018 Apr 30;8(11):3038-3058
pubmed: 29896301
Adv Drug Deliv Rev. 2008 May 22;60(8):915-28
pubmed: 18325628
J Biol Chem. 2011 Oct 7;286(40):34883-92
pubmed: 21849500
Nature. 2009 Jan 29;457(7229):557-61
pubmed: 19136945
Chembiochem. 2017 Sep 5;18(17):1721-1729
pubmed: 28618135
Oncoimmunology. 2015 Mar 06;4(2):e984547
pubmed: 25949881
Blood. 2008 Oct 1;112(7):2817-25
pubmed: 18669871
Blood. 2011 Oct 13;118(15):4111-9
pubmed: 21860028
Nanoscale. 2019 Apr 4;11(14):6990-7001
pubmed: 30916672
Trends Biotechnol. 2014 Jan;32(1):32-45
pubmed: 24210498
PLoS One. 2014 Jul 29;9(7):e103736
pubmed: 25072631
Eur J Pharm Sci. 2004 Aug;22(5):459-68
pubmed: 15265516
J Immunol. 2014 Jun 1;192(11):5002-11
pubmed: 24795456
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Sep;9(5):
pubmed: 28160452
BMC Cancer. 2011 Nov 30;11:504
pubmed: 22128892
Front Immunol. 2019 Jan 22;10:8
pubmed: 30723469
J Control Release. 2014 Dec 28;196:243-51
pubmed: 25456830
Nat Rev Mol Cell Biol. 2018 Nov;19(11):679-696
pubmed: 30194414
Br J Cancer. 2016 May 10;114(10):1071-7
pubmed: 27070712
Cancer Res. 2003 Jun 1;63(11):2836-43
pubmed: 12782589
Immunol Rev. 2012 Sep;249(1):158-75
pubmed: 22889221
Nanoscale. 2015 Aug 7;7(29):12728-36
pubmed: 26154916
J Am Chem Soc. 2015 Jan 21;137(2):770-5
pubmed: 25521540
J Immunother. 2013 Jan;36(1):11-9
pubmed: 23211625
J Immunol. 2007 Jan 15;178(2):748-56
pubmed: 17202335
Intervirology. 2013;56(3):141-65
pubmed: 23594863
J Exp Med. 2010 Aug 2;207(8):1791-804
pubmed: 20660615
Eur J Pharm Biopharm. 2011 Apr;77(3):417-23
pubmed: 21093587
Trends Immunol. 2019 Nov;40(11):984-997
pubmed: 31676264
Chem Soc Rev. 2017 Jul 17;46(14):4218-4244
pubmed: 28585944
Urol Oncol. 2006 Sep-Oct;24(5):419-24
pubmed: 16962494
Vaccine. 2007 May 22;25(21):4183-92
pubmed: 17399861
Biomaterials. 2014 Jan;35(2):814-24
pubmed: 24144906
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8845-55
pubmed: 16361574
Cancer Res. 2018 Dec 1;78(23):6643-6654
pubmed: 30297531
Bioconjug Chem. 2018 Apr 18;29(4):1047-1059
pubmed: 29446616
ACS Nano. 2015 Mar 24;9(3):3169-77
pubmed: 25715979
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Nat Rev Cancer. 2017 Nov;17(11):676-691
pubmed: 28984291
Nanomedicine. 2018 Aug;14(6):1919-1929
pubmed: 29885899
Adv Drug Deliv Rev. 2006 Nov 30;58(12-13):1379-408
pubmed: 17081649
Biomaterials. 2012 Apr;33(10):3025-35
pubmed: 22248990
Nat Rev Cancer. 2018 Dec;18(12):727-743
pubmed: 30405213
J Med Chem. 2010 Oct 14;53(19):6811-24
pubmed: 20666486
Molecules. 2015 Feb 26;20(3):3791-810
pubmed: 25730388
J Hematol Oncol. 2019 Apr 1;12(1):35
pubmed: 30935414
Int J Pharm. 2008 May 1;355(1-2):1-18
pubmed: 18343058
J Immunol. 2012 Mar 15;188(6):2687-94
pubmed: 22323546
Front Immunol. 2017 Sep 22;8:1178
pubmed: 29018445
Cancers (Basel). 2018 Jul 20;10(7):
pubmed: 30037052
Annu Rev Biochem. 2007;76:141-65
pubmed: 17362201
Front Immunol. 2018 Feb 19;9:262
pubmed: 29515580
J Immunol Res. 2019 Feb 6;2019:8795673
pubmed: 30882007
Nano Lett. 2006 Apr;6(4):662-8
pubmed: 16608261
Front Pharmacol. 2018 Aug 17;9:922
pubmed: 30174604
Int J Pharm. 2005 Jul 25;298(2):315-22
pubmed: 15961266
J Pharmacol Exp Ther. 2019 Sep;370(3):555-569
pubmed: 31175217
J Oncol. 2019 Feb 3;2019:5245034
pubmed: 30853982